Transgenic mice as an in vivo model of lymphomagenesis

International Review of Cytology

Volumn 236, Issue , 2004, Pages 123-180

  Tarantul, V Z ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

Author keywords

Genes; Human disease models; Lymphomagenesis; Malignant transformation; Transgenic mice

Indexed keywords

BRUTON TYROSINE KINASE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; ONCOPROTEIN; PEROXIREDOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P18; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR;

APOPTOSIS; B LYMPHOCYTE; CELL CYCLE; CELL DEATH; DATA ANALYSIS; DNA MODIFICATION; DNA REPAIR; ENZYME ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENE TECHNOLOGY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

MAMMALIA; MUS MUSCULUS;

EID: 3142677977     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(04)36004-3     Document Type: Article

References (252)

1. lck. Proc. Natl. Acad. Sci. USA. 88:1991;3977-3981
2. Acton D., Jacobs H., Domen J., Berns A. Bcl-2 reduces lymphomagenesis in deltaV-TCRbeta transgenic mice. Oncogene. 14:1997;2497-2501
3. Adams J.M., Cory S. Transgenic models of tumor development. Science. 251:1991;1161-1167
4. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enchancer induces lymphoid malignancy in transgenic mice. Nature. 318:1985;533-538
5. Alexander J. Use of transgenic mice in identifying chemopreventive agents. Toxicol. Lett. 112-113:2000;507-512
6. Alexander W.S., Schrader J.W., Adams J.M. Expression of the c-myc oncogene under control of an immunoglobulin enchancer in Eμ-myc transgenic mice. Mol. Cell. Biol. 7:1987;1436-1444
7. Alkema M.J., Jacobs H., van Lohuizen M., Berns A. Perturbation of B and T cell development and predisposition to lymphomagenesis in Eμ-Bmi1 transgenic mice require the Bmi RING finger. Oncogene. 15:1997;899-910
8. Allen J.D., Verhoeven E., Domen J., van der Valk M., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 15:1997;1133-1141
9. Alt J.R., Greiner T.C., Cleveland J.L., Eischen C.M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 22:2003;1442-1450
10. Altavilla G., Trabanelli C., Merlin M., Caputo A., Lanfredi M., Barbanti-Brodano G., Corallini A. Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virustat transgenic mice. Am. J. Pathol. 154:1999;1231-1244
11. Aplan P.D., Jones C.A., Chervinsky D.S., Zhao X., Ellsworth M., Wu C., McGuire E.A., Gross K.W. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 16:1997;2408-2419
12. Bachelier R., Xu X., Wang X., Li W., Naramura M., Gu H., Deng C.X. Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice. Oncogene. 22:2003;528-537
13. Badiani P.A., Kioussis D., Swirsky D.M., Lampert I.A., Weston K. T-cell lymphomas in v-myb transgenic mice. Oncogene. 13:1996;2205-2212
14. Bain G., Engel I., Robanus Maandag E.C., te Riele H.P., Voland J.R., Sharp L.L., Chun J., Huey B., Pinkel D., Murre C. E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol. 17:1997;4782-4791
15. Bassing C.H., Suh H., Ferguson D.O., Chua K.F., Manis J., Eckersdorff M., Gleason M., Bronson R., Lee C., Alt F.W. Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell. 114:2003;359-370
16. Batten M., Fletcher C., Ng L.G., Groom J., Wheway J., Laabi Y., Xin X., Schneider P., Tschopp J., Mackay C.R., Mackay F. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J. Immunol. 172:2004;812-822
17. Baudino T.A., Maclean K.H., Brennan J., Parganas E., Yang C., Aslanian A., Lees J.A., Sherr C.J., Roussel M.F., Cleveland J.L. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell. 11:2003;905-914
18. Baxter E.W., Blyth K., Donehower L.A., Cameron E.R., Onions D.E., Neil J.C. Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: Overlapping pathways in tumor development? J. Virol. 70:1996;2095-2100
19. Baxter E.W., Blyth K., Cameron E.R., Neil J.C. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice. J. Virol. 75:2001;9790-9798
20. Bellavia D., Campese A.F., Alesse E., Vacca A., Felli M.P., Balestri A., Stoppacciaro A., Tiveron C., Tatangelo L., Giovarelli M., Gaetano C., Ruco L., Hoffman E.S., Hayday A.C., Lendahl U., Frati L., Gulino A., Screpanti I. Constitutive activation of NF-kappaB and T-cell leukemialymphoma in Notch3 transgenic mice. EMBO J. 19:2000;3337-3348
21. Belli B., Wolf L., Nazarov V., Fan H. Proviral activation of the c-myb proto-oncogene is detectable in preleukemic mice infected neonatally with Moloney murine leukemia virus but not in resulting end stage T lymphomas. J. Virol. 69:1995;5138-5141
22. Beneke R., Moroy T. Inhibition of poly(ADP-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice. Oncogene. 20:2001;8136-8141
23. Benvenisty N., Ornitz D.M., Bennet G.L., Sahagan B.S., Kuo A., Cardiff R.D., Leder P. Brain tumors and lymphomas in transgenic mice that carry HTLV-I LTRc-myc and Igtax gene. Oncogene. 7:1992;2399-2405
24. Bernardi R., Grisendi S., Pandolfi P.P. Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene. 21:2002;3445-3458
25. Blyth K., Terry A., O'Hara M., Baxter E.W., Campbell M., Stewart M., Donehower L.A., Onions D.E., Neil J.C., Cameron E.R. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: Contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 10:1995;1717-1723
26. Blyth K., Terry A., Mackay N., Vaillant F., Bell M., Cameron E.R., Neil J.C., Stewart M. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene. 20:2001;295-302
27. Borlado L.R., Redondo C., Alvarez B., Jimenez C., Criado L.M., Flores J., Marcos M.A., Martinez-A C., Balomenos D., Carrera A.C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14:2000;895-903
28. Brabb T., Rubicz R., Mannikko V., Goverman J. Separately expressed T cell receptor alpha and beta chain transgenes exert opposite effects on T cell differentiation and neoplastic transformation. Eur. J. Immunol. 27:1997;3039-3048
29. Breuer M.L., Cuypers H.T., Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 8:1989a;743-747
30. Breuer M., Slebos R., Verbeek S., van Lohuizen M., Wientjiens E., Berns A. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature. 340:1989b;61-63
31. Breuer M., Wientjiens E., Verbeek S., Slebos R., Berns A. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: Dose dependence and involvement of myc and ras. Cancer Res. 51:1991;958-963
32. Brown M.P., Topham D.J., Sangster M.Y., Zhano J., Flynn K.J., Surman S.L., Woodland D.L., Doherty P.C., Farr A.G., Pattengale P.K., Brenner M.K. Thymic lymphoproliferative disease after successful correction of Cd40 ligand deficiency by gene transfer in mice. Nat. Med. 4:1998;1253-1260
33. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., Grupp S.A. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc. Natl. Acad. Sci. USA. 100:2003;15113-15118
34. Butzler C., Zou X., Popov A.V., Bruggemann M. Rapid induction of B-cell lymphomas in mice carrying a human IgHc-mycYAC. Oncogene. 14:1997;1383-1388
35. Cameron E.R., Blyth K., Hanlon L., Kilbey A., Mackay N., Stewart M., Terry A., Vaillant F., Wotton S., Neil J.C. The Runx genes as dominant oncogenes. Blood Cells Mol. Dis. 30:2003;194-200
36. Carrasco D., Rizzo C.A., Dorfman K., Bravo R. The v-rel oncogene promotes malignant T-cell leukemialymphoma in transgenic mice. EMBO J. 15:1996;3640-3650
37. Ceci J.D., Patriotis C.P., Tsatsanis C., Makris A.M., Kovatch R., Swing D.A., Jenkins N.A., Tsichlis P.N., Copeland N.G. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 11:1997;688-700
38. Celeste A., Difilippantonio S., Difilippantonio M.J., Fernandez-Capetillo O., Pilch D.R., Sedelnikova O.A., Eckhaus M., Ried T., Bonner W.M., Nussenzweig A. H2AX haploinsufficiency modifies genomic instability and tumor susceptibility. Cell. 114:2003;371-383
39. Channavajhala P., Seldin D.C. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 21:2002;5280-5288
40. Chen J., Neilson K., Van Dyke T. Lymphotropic papovavirus early region is specifically regulated in transgenic mice and efficiently induces neoplasia. J. Virol. 63:1989;2204-2214
41. Condorelli G.L., Facchiano F., Valtieri M., Proietti E., Vitelli L., Lulli V., Huebner K., Peschle C., Croce C.M. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res. 56:1996;5113-5119
42. Cory S., Harris A.W., Strasser A. Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 345:1994;289-295
43. Cory S., Vaux D.L., Strasser A., Harris A.W., Adams J.M. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res. 59:1999;1685s-1692s
44. Curtis D.J., Robb L., Strasser A., Begley C.G. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. Oncogene. 15:1997;2975-2983
45. Davies J., Badiani P., Weston K. Cooperation of Myb and Myc proteins in T cell lymphomagenesis. Oncogene. 18:1999;3643-3647
46. Dedera D.A., Waller E.K., LeBrun D.P., Sen-Majumdar A., Stevens M.E., Barsh G.S., Cleary M.L. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell. 74:1993;833-843
47. de Wind N., Dekker M., Claij N., Jansen L., van Klink Y., Radman M., Riggins G., van der Valk M., van't Wout K., te Riele H. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat. Genet. 23:1999;359-362
48. Diaz R., Ahn D., Lopez-Barcons L., Malumbres M., Perez de Castro I., Lue J., Ferrer-Miralles N., Mangues R., Tsong J., Garcia R., Perez-Soler R., Pellicer A. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 62:2002;4514-4518
49. Difilippantonio M.J., Petersen S., Chen H.T., Johnson R., Jasin M., Kanaar R., Ried T., Nussenzweig A. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J. Exp. Med. 196:2002;469-480
50. Dildrop R., Ma A., Zimmerman K., Hsu E., Tesfaye A., DePinho R., Alt F.W. IgH encancer-mediated deregulation of N-myc gene expression in transgenic mice: Generation of lymphoid neoplasias that lack c-myc expression. EMBO J. 8:1989;1121-1128
51. Dolcetti R., Rizzo S., Viel A., Maestro R., De Re V., Feriotto G., Boiocchi M. N-myc activation by proviral in MCF 247-induced murine T-cell lymphomas. Oncogene. 4:1989;1009-1014
52. Donehower L., Harvey M., Slagle B., Montgomery C., Janet B. p53-deficient mice develop normally but are susceptible to tumors. J. Cell. Biochem. Suppl. 16B:1992;114
53. Drotar M.E., Silva S., Barone E., Campbell D., Tsimbouri P., Jurvansu J., Bhatia P., Klein G., Wilson J.B. Epstein-Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis. Int. J. Cancer. 106:2003;388-395
54. Egle A., Harris A.W., Bath M.L., O'Reilly L., Cory S. vavP-bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 103:2003;2276-2283
55. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13:1999;2658-2669
56. Eischen C.M., Roussel M.F., Korsmeyer S.J., Cleveland J.L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21:2001;7653-7662
57. Ek S., Hogerkorp C.M., Dictor M., Ehinger M., Borrebaeck C.A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 62:2002;4398-4405
58. Elson A., Deng C., Campos-Torres J., Donehower L.A., Leder P. The MMTVc-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene. 11:1995;181-190
59. Embree-Ku M., Boekelheide K. FasL deficiency enhances the development of tumors in p53+- mice. Toxicol. Pathol. 30:2002;705-713
60. Engel I., Murre C. Disruption of pre-TCR expression accelerates lymphomagenesis in E2A-deficient mice. Proc. Natl. Acad. Sci. USA. 99:2002;11322-11327
61. Feldman B.J., Reid T.R., Cleary M.L. Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice. Oncogene. 15:1997;2735-2742
62. Feldman B.J., Hampton T., Cleary M.L. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood. 96:2000;1906-1913
63. Fisch P., Boehm T., Lavenir I., Larson T., Arno J., Forster A., Rabbitts T.H. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 7:1992;2389-2397
64. Fisher A.G., Burdet C., Bunce C., Merkenschlager M., Ceredig R. Lymphoproliferative disorders in IL-7 transgenic mice: Expansion of immature B cells which retain macrophage potential. Int. Immunol. 7:1995;415-423
65. Flemming A., Brummer T., Reth M., Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat. Immunol. 4:2003;38-43
66. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. USA. 88:1991;5413-5417
67. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science. 300:2003;489-492
68. Geisen C., Karsunky H., Yucel R., Moroy T. Loss of p27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis. Oncogene. 22:2003;1724-1729
69. Girard L., Jolicoeur P. A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTVmyc transgenic mice. Oncogene. 16:1998;517-522
70. Girard L., Hanna Z., Beaulieu N., Hoemann C.D., Simard C., Kozak C.A., Jolicoeur P. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVDmyc transgenic mice suggests a collaboration of c-myc and notch1 for oncogenesis. Genes Dev. 10:1996;1930-1944
71. Gordon J.W., Scangos G.A., Plotkin D.J., Barbosa J.A., Ruddle F.H. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. USA. 77:1980;7380-7384
72. Greenwald R.J., Tumang J.R., Sinha A., Currier N., Cardiff R.D., Rothstein T.L., Faller D.V., Denis G.V. Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood. 103:2004;1475-1484
73. Gu Y., Seidl K.J., Rathbun G.A., Zhu C., Manis J.P., van der Stoep N., Davidson L., Cheng H.L., Sekiguchi J.M., Frank K., Stanhope-Baker P., Schlisse M.S., Roth D.B., Alt F.W. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity. 7:1997;653-665
74. Guidos C.J., Williams C.J., Grandal I., Knowles G., Huang M.T., Danska J.S. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 10:1996;2038-2054
75. AFR. Cell. 91:1997;555-558
76. Haidar M.A., Manshouri T., Keating M.J., Kantarjian H.M., Freireich E.J., Mehta K., Albitar M. Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. Int. J. Oncol. 16:2000;561-565
77. Harris A.V., Pinkert C.A., Crawford M., Langdon W.Y., Brinster R.L., Adams J.M. The Emu-myc transgenic mouse: A model for high-incidence spontaneous lymphoma and leukemia of early B cell. J. Exp. Med. 167:1988;353-371
78. Harris N.L. A practical approach to the pathology of lymphoid neoplasms: A revised European-American classification from the International Lymphoma Study Group. Important Adv. Oncol. 1995;111-140
79. Haupt Y., Alexander W.S., Barri G., Klinken S.P., Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accellerated lymphomagenesis in Eμ-myc transgenic mice. Cell. 65:1991;753-763
80. Haupt Y., Harris A.W., Adams J.M. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene. 7:1992;981-986
81. Haupt Y., Bath M.L., Harris A.W., Adams J.M. bmi-1 transgene induces lymphomes and collaborates with myc in tumorigenesis. Oncogene. 8:1993;3161-3164
82. Hemann M.T., Fridman J.S., Zulfou J.T., Hernando E., Paddison P.J., Cordon-Cardo C., Hannon G.J., Lowe S.W. An epi-allelic series of p53 hypomorphs created by stable RNAi produced distinct tumor phenotypes in vivo. Nat. Genet. 33:2003;396-400
83. Hemmeryckx B., van Wijk A., Reichert A., Kaartinen V., de Jong R., Pattengale P.K., Gonzalez-Gomez I., Groffen J., Heisterkamp N. Crkl enhances leukemogenesis in BCRABL P190 transgenic mice. Cancer Res. 61:2001;1398-1405
84. Hough M.R., Reis M.D., Singaraja R., Bryce D.M., Kamel-Reid S., Dardick I., Breitman M.L., Dube I.D. A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc. Natl. Acad. Sci. USA. 95:1998;13853-13858
85. Hoyer K.K., French S.W., Turner D.E., Nguyen M.T., Renard M., Malone C.S., Knoetig S., Qi C.F., Su T.T., Cheroutre H., Wall R., Rawlings D.J., Morse H.C. 3rd, Teitell M.A. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc. Natl. Acad. Sci. USA. 99:2002;14392-14397
86. Hwang H.C., Martins C.P., Bronkhorst Y., Randel E., Berns A., Fero M., Clurman B.E. Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc. Natl. Acad. Sci. USA. 99:2002;11293-11298
87. Iozzo R.V., Chakrani F., Perrotti D., McQuillan D.J., Skorski T., Calabretta B., Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. USA. 96:1999;3092-3097
88. Ishikawa T., Shibuya K., Yasui K., Mitamura K., Ueda S. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp. Immunol. Microbiol. Infect. Dis. 26:2003;115-124
89. Jacobs H., Ossendorp F., de Vries E., Ungewiss K., von Boehmer H., Borst J., Berns A. Oncogenic potential of a pre-T cell receptor lacking the TCR beta variable domain. Oncogene. 12:1996;2089-2099
90. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4aARF. Genes Dev. 13:1999;2678-2690
91. Jaenisch R., Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA. 71:1974;1250-1254
92. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208
93. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA. 95:1998;15608-15612
94. Jonkers J., Korswagen H.C., Acton D., Breuer M., Berns A. Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J. 16:1997;441-450
95. Jonkers J., Weening J.J., van der Valk M., Bobeldijk R., Berns A. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene. 18:1999;5982-5990
96. Kamijo T., Bodner S., van de Kamp E., Randle D.H., Sherr C.J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:1999;2217-2222
97. Kang J., Bronson R.T., Xu Y. Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair. EMBO J. 21:2002;1447-1455
98. Karsunky H., Geisen C., Schmidt T., Haas K., Zevnik B., Gau E., Moroy T. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: Evidence for cooperation between cyclin E and Ras but not Myc. Oncogene. 18:1999;7816-7824
99. Kawate H., Itoh R., Sakumi K., Nakabeppu Y., Tsuzuki T., Ide F., Ishikawa T., Noda T., Nawata H., Sekiguchi M. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis. 21:2000;301-305
100. Kelliher M.A., Seldin D.C., Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II alpha. EMBO J. 15:1996;5160-5166
101. Kelly J.A., Spolski R., Kovanen P.E., Suzuki T., Bollenbacher J., Pise-Masison C.A., Radonovich M.F., Lee S., Jenkins N.A., Copeland N.G., Morse H.C. 3rd, Leonard W.J. Stat5 synergizes with T cell receptorantigen stimulation in the development of lymphoblastic lymphoma. J. Exp. Med. 198:2003;79-89
102. Kersseboom R., Middendorp S., Dingjan G.M., Dahlenborg K., Reth M., Jumaa H., Hendriks R.W. Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in pre-B cells. J. Exp. Med. 198:2003;91-98
103. Kisseljov F.L. Virus-associated human tumors: Cervical carcinomas and papilloma viruses. Biochemistry (Mosc). 65:2000;68-77
104. Knudson C.M., Johnson G.M., Lin Y., Korsmeyer S.J. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res. 61:2001;659-665
105. Kobzdej M., Matuszyk J., Strzadala L. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice. Leuk. Res. 24:2000;33-38
106. Kovalchuk A.L., Qi C.F., Torrey T.A., Taddesse-Heath L., Feigenbaum L., Park S.S., Gerbitz A., Klobeck G., Hoertnagel K., Polack A., Bornkamm G.W., Janz S., Morse H.C. 3rd. Burkitt lymphoma in the mouse. J. Exp. Med. 192:2000;1183-1190
107. Kovalchuk A.L., Kim J.S., Park S.S., Coleman A.E., Ward J.M., Morse H.C. 3rd, Kishimoto T., Potter M., Janz S. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc. Natl. Acad. Sci. USA. 99:2002;1509-1514
108. Kovalev G.I., Franklin D.S., Coffield V.M., Xiong Y., Su L. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J. Immunol. 167:2001;3285-3292
109. Kretschmer C., Murphy C., Biesinger B., Beckers J., Fickenscher H., Kirchner T., Fleckenstein B., Ruther U. A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice. Oncogene. 12:1996;1609-1616
110. Kruger A., Fata J.E., Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood. 90:1997;1993-2000
111. Kulwichit W., Edwards R.H., Davenport E.M., Baskar J.F., Godfrey V., Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA. 95:1998;11963-11968
112. Kundu R.K., Sangiorgi F., Wu L.Y., Pattengale P.K., Hinton D.R., Gill P.S., Maxson R. Expression of the human immunodeficiency virus-tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 94:1999;275-282
113. Landesman-Bollag E., Channavajhala P.L., Cardiff R.D., Seldin D.C. p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene. 16:1998;2965-2974
114. Langdon W.Y., Harris A.W., Cory S., Adams J.M. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell. 47:1986;11-18
115. Langdon W.Y., Harris A.W., Cory S. Growth of Eμ-myc transgenic B lymphoid cells in vitro and their evolution towards autonomy. Oncogene Res. 3:1988;271-279
116. Langdon W.Y., Harris A.W., Cory S. Acceleration of B-lymphoid tumorigenesis in Eμ-myc transgenic mice by v-Ha-ras and v-raf but not v-abl. Oncogene Res. 4:1989;253-258
117. Lange K., Uckert W., Blankenstein T., Nadrowitz R., Bittner C., Renauld J.C., van Snick J., Feller A.C., Merz H. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene. 22:2003;517-527
118. Larson R.C., Fisch P., Larson T.A., Lavenir I., Langford T., King G., Rabbitts T.H. T cell tumours of disparate phenotype in mice transgenic for rbtn-2. Oncogene. 9:1994;3675-3681
119. Larson R.C., Lavenir I., Larson T.A., Baer R., Warren A.J., Wadman I., Nottage K., Rabbitts T.H. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15:1996;1021-1027
120. Latres E., Chiarle R., Schulman B.A., Pavletich N.P., Pellicer A., Inghirami G., Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA. 98:2001;2515-2520
121. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:1989;3982-3991
122. Le Beau M. Chromosomal abnormalities in non-Hodgkin's lymphomas. Semin. Oncol. 17:1990;20-29
123. Leder A., Pattengale P.K., Kuo A., Stewart T.A., Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell. 45:1986;485-495
124. Li Q., Yoshioka N., Yutsudo M., Inafuku S., Aozasa K., Kitamura Y., Aizawa S., Nishimune Y., Hakura A., Kondoh G. Human papillomavirus-induced carcinogenesis with p53 deficiency in mouse: Novel lymphomagenesis in HPV16E6E7 transgenic mice mimicking p53 defect. Virology. 252:1998;28-33
125. Lim D.S., Vogel H., Willerford D.M., Sands A.T., Platt K.A., Hasty P. Analysis of ku80-mutant mice and cells with deficient level p53. Mol. Cell. Biol. 20:2000;3772-3780
126. Lin K., Abraham K.M. Targets of p56(lck) activity in immature thymoblasts: Stimulation of the RasRafMAPK pathway. Int. Immunol. 9:1997;291-306
127. Linardopoulos S., Silva S., Klein G., Balmain A. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc or N-myc transgenes. Int. J. Cancer. 88:2000;920-927
128. Lindeman G.J., Harris A.W., Bath M.L., Eisenman R.N., Adams J.M. Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. Oncogene. 10:1995;1013-1017
129. Linette G.P., Hess J.L., Sentman C.L., Korsmeyer S.J. Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. Blood. 86:1995;1255-1260
130. Lovec H., Grzeschiczek A., Kowalski M.B., Moroy T. Cyclin D1bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 13:1994;3487-3495
131. Lowsky R., DeCoteau J.F., Reitmair A.H., Ichinohasama R., Dong W.F., Xu Y., Mak T.W., Kadin M.E., Minden M.D. Defects of the mismatch repair gene msh2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and tal-1 (scl). Blood. 89:1997;2276-2282
132. Luke J.J., Van De Wetering C.I., Knudson C.M. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell. Death Differ. 10:2003;740-748
133. Ma A., Smith R.K., Tesfaye A., Achacoso P., Dildrop R., Rosenberg N., Alt F.W. Mechanism of endogenous myc gene down-regulation in Eμ-N-myc tumors. Mol. Cell. Biol. 11:1991;440-444
134. Ma A., Fisher P., Dildrop R., Oltz E., Rathbun G., Achacoso P., Stall A., Alt F.W. Surface IgM mediated regulation of RAG gene expression in Emu-N-myc B cell lines. EMBO J. 11:1992;2727-2734
135. Malek S.N., Dordai D.I., Reim J., Dintzis H., Desiderio S. Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc. Natl. Acad. Sci. USA. 95:1998;7351-7356
136. Mangues R., Symmans W.F., Lu S., Schwartz S., Pellicer A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene. 13:1996;1053-1063
137. Mangues R., Corral T., Kohl N.E., Symmans W.F., Lu S., Malumbres M., Gibbs J.B., Oliff A., Pellicer A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58:1998;1253-1259
138. Manshouri T., Yang Y., Lin H., Stass S.A., Glassman A.B., Keating M.J., Albitar M. Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RARbeta and RARgamma and development of lymphoma. Blood. 89:1997;2507-2515
139. Marin M.C., Hsu B., Stephens L.C., Brisbay S., McDonnell T.J. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp. Cell Res. 217:1995;240-247
140. Martins C.P., Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 21:2002;3739-3748
141. McDonnell T.J., Korsmeyer S. Murine model of the t(14;18) progresses from lymphoid hyperplasia to high grade malignant lymphoma. Nature. 349:1991;254-256
142. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P., Korsmeyer S.J. bci-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79-88
143. McGuire E.A., Rintoul C.E., Sclar G.M., Korsmeyer S.J. Tymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemialymphoma. Mol. Cell. Biol. 12:1992;4186-4196
144. Mehtali M., Munschy M., Cailleud J.M., Kieny M.-P. HIV regulatory genes induce AIDS-like pathologies in transgenic mice. Valette L. "Colloque des Cets Gardes" 1991;25-30 Girard M. Lyon, Fondation, Merieux
145. Menke A.L., Clarke A.R., Leitch A., Ijpenberg A., Williamson K.A., Spraggon L., Harrison D.J., Hastie N.D. Genetic interactions between the Wilms' tumor 1 gene and the p53 gene. Cancer Res. 62:2002;6615-6620
146. Mikkers H., Allen J., Berns A. Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in Emu-myc transgenic mice. Oncogene. 21:2002a;6559-6566
147. Mikkers H., Allen J., Knipscheer P., Romeijn L., Hart A., Vink E., Berns A., Romeyn L. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat. Genet. 32:2002b;153-159
148. Miller C. Fields B.N.,, et al. "Virology" 2nd Ed. 1990;563-589 Raven Press, New York
149. Morello D., Lavenu A., Bandeira A., Portnoi D., Gaillard J., Babinet C. Lymphoproliferative syndrome associated with c-myc expression driven by a class I gene promoter in transgenic mice. Oncogene Res. 4:1989;111-125
150. Moroy T., Fisher P., Guidos C., Ma A., Zimmerman K., Tesfaye A., DePinho R., Weissman I., Alt F.W. IgH enchancer deregulated expression of L-myc: Abnormal T lymphocyte development and T cell lymphomagenesis. EMBO J. 9:1990;3659-3666
151. Moroy T., Verbeek S., Ma A., Achacoso P., Berns A., Alt F. Eμ-N- and Eμ-L-myc cooperate with Eμ-pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene. 6:1991;1941-1948
152. Moroy T., Grzeschiczek A., Petzold S., Hartmann K.-U. Expression of a pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lprlpr mice. Proc. Natl. Acad. Sci. USA. 90:1993;10734-10738
153. Morrison C., Smith G.C., Stingl L., Jackson S.P., Wagner E.F., Wang Z.Q. Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat. Genet. 17:1997;479-482
154. Mucenski M.L., Gilbert D.J., Taylor B.A., Jenkins N.A., Copeland N.G. Common sites of viral integration in lymphomas arising in AKXD recombinant inbred mouse strains. Oncogene Res. 2:1987;33-48
155. Nakayama K., Nagahama H., Minamishima Y.A., Matsumoto M., Nakamichi I., Kitagawa K., Shirane M., Tsunematsu R., Tsukiyama T., Ishida N., Kitagawa M., Nakayama K., Hatakeyama S. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19:2000;2069-2081
156. Nawijn M.C., Ferreira R., Dingjan G.M., Kahre O., Drabek D., Karis A., Grosveld F., Hendriks R.W. Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and induces thymic lymphoma in transgenic mice. J. Immunol. 167:2001;715-723
157. Neale G.A., Rehg J.E., Goorha R.M. Ectopic expression of rhombotin-2 causes selective expansion of the thymus and T-cell tumors in transgenic mice.
158. Neale G.A., Rehg J.E., Goorha R.M. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia. 11:1997;289-290
159. Nerenberg M., Hinrichs S.H., Reynolds R.K., Khoury G., Jay G. The tat gene of human T lymphotropic virus type I induces mesenchymal tumors in transgenic mice. Science. 237:1987;1324-1329
160. Nerenberg M.I., Minor T., Price J., Ernst D.N., Shinohara T., Schwarz H. Transgenic thymocytes are refractory to transformation by the human T-cell leukemia virus type I tax gene. J. Virol. 65:1991;3349-3353
161. Neumann C.A., Krause D.S., Carman C.V., Das S., Dubey D.P., Abraham J.L., Bronson R.T., Fujiwara Y., Orkin S.H., Van Etten R.A. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 424:2003;561-565
162. Nikitin A.Y., Liu C.Y., Flesken-Nikitin A., Chen C.F., Chen P.L., Lee W.H. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in msh2( - )Rb(+-) mice. Cancer Res. 62:2002;5134-5138
163. Nilsen H., Stamp G., Andersen S., Hrivnak G., Krokan H.E., Lindahl T., Barnes D.E. Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas. Oncogene. 22:2003;5381-5386
164. Okazaki I.M., Hiai H., Kakazu N., Yamada S., Muramatsu M., Kinoshita K., Honjo T. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197:2003;1173-1181
165. O'Neil J., Billa M., Oikemus S., Kelliher M. The DNA binding activity of TAL-1 is not required to induce leukemialymphoma in mice. Oncogene. 20:2001;3897-3905
166. Ong S.T., Le Beau M.M. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin. Oncol. 25:1998;447-460
167. Pan L., Hanrahan J., Li J., Hale L.P., Zhuang Y. An analysis of T cell intrinsic roles of E2A by conditional gene disruption in the thymus. J. Immunol. 168:2002;3923-3932
168. Pattengale P.K., Taylor C.R. Experimental models of lymphoproliferative disease: The mouse as a model for human non-Hodgkin's lymphomas related leukemias. Am. J. Pathol. 113:1983;237-265
169. Pena J.C., Rudin C.M., Thompson C.B. A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res. 58:1998;2111-2116
170. Piva R., Liu J., Chiarle R., Podda A., Pagano M., Inghirami G. In Vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol. Cell. Biol. 22:2002;8375-8387
171. Portis T., Dyck P., Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood. 102:2003;4166-4178
172. Prakash O., Tan Z.Y., Peng X., Coleman R., Gill J., Farr G., Samaniego F. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J. Natl. Cancer Inst. 94:2002;926-935
173. Press R.D., Wisner T.W., Ewert D.L. Induction of B cell lymphomas by overexpression of a myb oncogene truncated at either terminus. Oncogene. 11:1995;525-535
174. Qin X.F., Luo Y., Suh H., Wayne J., Misulovin Z., Roeder R.G., Nussenzweig M.C. Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J. 13:1994;5967-5976
175. Qin X., Zhou H., Liu L., Gerson S.L. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis. 20:1999;1667-1673
176. Rabbitts T.H. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev. 12:1998;2651-2657
177. Ranger A.M., Zha J., Harada H., Datta S.R., Danial N.N., Gilmore A.P., Kutok J.L., Le Beau M.M., Greenberg M.E., Korsmeyer S.J. Bad-deficient mice develop diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA. 100:2003;9324-9329
178. Rathmell J.C., Elstrom R.L., Cinalli R.M., Thompson C.B. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33:2003;2223-2232
179. Reitmair A.H., Schmits R., Ewel A., Bapat B., Redston M., Mitri A., Waterhouse P., Mittrucker H.W., Wakeham A., Liu B., et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat. Genet. 11:1995;64-70
180. Renard C.A., Transy C., Tiollai P., Buendia M.A. Infection of WHVc-myc transgenic mice with Moloney murine leukaemia virus and proviral insertion near the syndecan-4 gene in an early liver tumour. Res. Virol. 149:1998;133-143
181. Renauld J.C., van der Lugt N., Vink A., van Roon M., Godfraind C., Warnier G., Merz H., Feller A., Berns A., Van Snick J. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene. 9:1994;1327-1332
182. Robb L., Rasko J.E., Bath M.L., Strasser A., Begley C.G. scl, a gene frequently activated in human T cell leukaemia, does not induce lymphomas in transgenic mice. Oncogene. 10:1995;205-209
183. Roberts C.W., Leroux M.M., Fleming M.D., Orkin S.H. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2:2002;415-425
184. Rockwood L.D., Torrey T.A., Kim J.S., Coleman A.E., Kovalchuk A.L., Xiang S., Ried T., Morse H.C. 3rd, Janz S. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene. 21:2002;7235-7240
185. Rosenbaum H., Webb E., Adams J.M., Cory S., Harris A.W. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. EMBO J. 8:1989;749-755
186. Sacco M.G., Ungari M., Cato E.M., Villa A., Strina D., Notarangelo L.D., Jonkers J., Zecca L., Facchetti F., Vezzoni P. Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 7:2000;1299-1306
187. Saggioro D., D'agostino D.M., Chieco-Bianchi L. Analysis of Tax-expressing cell lines generated from HTLV-I tax-transgenic mice: Correlation between c-myc overexpression and neoplastic potential. Exp. Cell Res. 247:1999;525-533
188. Scheijen B., Jonkers J., Acton D., Berns A. Characterisation of pal-1, a common proviral insertion site in murine leukemia virus-indused lymphomas of c-myc and pim-1 transgenic mice. J. Virol. 71:1997;9-16
189. Schmidt E.V., Pattengale P.K., Weir L., Leder P. Transgenic mice bearing the human c-myc gene activated by immunoglobulin enhancer: A pre-B lymphoma model. Proc. Natl. Acad. Sci. USA. 85:1988;6047-6051
190. Schmidt T., Zornig M., Beneke R., Moroy T. MoMuLV proviral integrations identified by Sup-F selection in tumors from infected mycpim bitransgenic mice correlate with activation of the gfi-1 gene. Nucleic Acids Res. 24:1996;2528-2534
191. Schmidt T., Karsunky H., Gau E., Zevnik B., Elsasser H.P., Moroy T. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene. 17:1998;2661-2667
192. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4aARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:1999;2670-2677
193. Schuldiner O., Benvenisty N. A DNA microarray screen for genes involved in c-myc and N-myc oncogenesis in human tumors. Oncogene. 20:2001;4984-4994
194. Seldin D.C., Leder P. Casein kinase II alpha transgene-induced murine lymphoma: Relation to theileriosis in cattle. Science. 267:1995;894-897
195. Selten G., Cuypers H.T., Berns A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J. 4:1985;1793-1798
196. Seo J.S., Park Y.M., Kim J.I., Shim E.H., Kim C.W., Jang J.J., Kim S.H., Lee W.H. T cell lymphoma in transgenic mice expressing the human Hsp70 gene. Biochem. Biophys. Res. Commun. 218:1996;582-587
197. Sethupathi P., Spieker-Polet H., Polet H., Yam P.C., Tunyaplin C., Knight K.L. Lymphoid and non-lymphoid tumors in Ek-myc transgenic rabbits. Leukemia. 8:1994;2144-2155
198. Sheppard R.D., Samant S.A., Rosenberg M., Silver L.M., Cole M.D. Transgenic N-myc mouse model for indolent B cell lymphoma: Tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors. Oncogene. 17:1998;2073-2085
199. Shinto Y., Moromoto M., Katsumata M., Uchida A., Aozasa K., Okamoto M., Kurosawa T., Ochi T., Greene M.I., Tsujimoto Y. Moloney murine leukemia virus infection accelerates lymphomagenesis in Emu-bcl-2 transgenic mice. Oncogene. 11:1995;1729-1736
200. Smith K.S., Rhee J.W., Naumovski L., Cleary M.L. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. Mol. Cell. Biol. 19:1999;4443-4451
201. Speth C., Luz A., Strauss P.G., Wendel S., Zeidler R., Dorn S., Erfle V., Brem G., Lipp M., Schmidt J. Akv murine leukemia virus enhances lymphomagenesis in myc-kappa transgenic and in wild-type mice. Virology. 206:1995;93-99
202. Stewart M., Terry A., O'Hara M., Cameron E., Onions D.E., Neil J.C. til-1: A novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. J. Gen. Virol. 77:1996;443-446
203. Stewart M., Terry A., Hu M., O'Hara M., Blyth K., Baxter E., Cameron E., Onions D.E., Neil J.C. Proviral insertions induce the expression of bone-specific isoforms of PEBR2aA (CBFA1): Evidence for a new myc colloborating oncogene. Proc. Natl. Acad. Sci. USA. 94:1997;8646-8651
204. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:1990;331-333
205. Strasser A., Harris A.W., Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 67:1991;889-899
206. Strasser A., O'Connor L., Huang D.C., O'Reilly L.A., Stanley M.L., Bath M.L., Adams J.M., Cory S., Harris A.W. Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Behring Inst. Mitt. 97:1996;101-117
207. Street S.E., Trapani J.A., MacGregor D., Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med. 196:2002;129-134
208. Suda Y., Aizawa S., Hirai S.-I., Inoue T., Furuta Y., Suzuki M., Hirohashi S., Ikawa Y. Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumor, myc induced pre-B lymphomas and SV40 large T gene a variety of tumors in transgenic mice. EMBO J. 6:1987;4055-4065
209. Suda Y., Shinichi A., Yasuhide F., Takeshi Y., Yoji I., Saitoh K., Yamada Y., Toyoshima K., Yamamoto T. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with mutated gene (Val659-Glu659). EMBO J. 9:1990;181-190
210. Suzuki A., Yamaguchi M.T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., Tsubata T., Ohashi P.S., Koyasu S., Penninger J.M., Nakano T., Mak T.W. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 14:2001;523-534
211. Talora C., Campese A.F., Bellavia D., Pascucci M., Checquolo S., Groppioni M., Frati L., Von Boehmer H., Gulino A., Screpanti I. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep. 4:2003;1067-1071
212. Tarantul V.Z., Nikolaev A.I., Martynenko A., Hannig H., Hunsmann G., Bodemer W. Differential gene expression in B-cell non-Hodgkin's lymphoma of SIV-infected monkey. AIDS Res. Hum. Retroviruses. 16:2000;173-179
213. Tarantul V., Nikolaev A., Hannig H., Kalmyrzaev B., Muchoyan I., Maximov V., Nenasheva V., Dubovaya V., Hunsmann G., Bodemer W. Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin's lymphoma. Neoplasia. 3:2001;132-142
214. Teitell M., Damore M.A., Sulur G.G., Turner D.E., Stern M.H., Said J.W., Denny C.T., Wall R. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc. Natl. Acad. Sci. USA. 96:1999;9809-9814
215. Tomasson M.H., Williams I.R., Hasserjian R., Udomsakdy C., McGrath S.M., Schwaller J., Druker B., Gilliland D.G. TELPDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood. 93:1999;1707-1714
216. Trinh B.N., Long T.I., Nickel A.E., Shibata D., Laird P.W. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell. Biol. 22:2002;2906-2917
217. Tsimbouri P., Drotar M.E., Coy J.L., Wilson J.B. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in Eμ-EBNA-1 transgenic mouse lymphocytes. Oncogene. 21:2002;5182-5187
218. Turner S.D., Tooze R., Maclennan K., Alexander D.R. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene. 22:2003;7750-7761
219. Vaillant F., Blyth K., Terry A., Bell M., Cameron E.R., Neil J., Stewart M. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 18:1999;7124-7134
220. Vaillant F., Blyth K., Andrew L., Neil J.C., Cameron E.R. Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J. Immunol. 169:2002;2866-2874
221. van der Lugt N.M., Domen J., Verhoeven E., Linders K., van der Gulden H., Allen J., Berns A. Proviral tagging in Eμ-myc transgenic mice lacking the pim-1 proto-oncogene leads to compensatory activation of pim-2. EMBO J. 14:1995;2536-2544
222. van Dyk L.F., Hess J.L., Katz J.D., Jacoby M., Speck S.H., Virgin H.W. IV. The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes. J. Virol. 73:1999;5110-5122
223. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 97:2001;3896-3901
224. van Kreijl C.F., van der Houven van Ordt C.W., Kroese E.D., Sorensen I.K., Breuer M.L., Storer R.D. Evaluation of the Eμ-pim-1 transgenic mouse model for short-term carcinogenicity testing. Toxicol. Pathol. 26:1998;750-756
225. van Lohuizen M., Breuer M., Berns A. N-myc is frequently activated by proviral insertion in MuLV-induced T-cell lymphomas. EMBO J. 8:1989a;133-136
226. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 56:1989b;673-682
227. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus integration. Cell. 65:1991;737-752
228. van Meyel D.J., Sanchez-Sweatman O.H., Kerkvliet N., Stitt L., Ramsay D.A., Khokha R., Chambers A.F., Cairncross J.G. Genetic background influences timing, morphology and dissemination of lymphomas in p53-deficient mice. Int. J. Oncol. 13:1998;917-922
229. Verbeek S., van Lohuizen M., van der Valk M., Domen J., Kraal G., Berns A. Mice bearing the Eμ-myc and Eμ-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 11:1991;1176-1179
230. Verschuren E.W., Klefstrom J., Evan G.I., Jones N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell. 2:2002;229-241
231. Wang B., She J., Salio M., Allen D., Lacy E., Lonberg N., Terhorst C. CD3-epsilon overexpressed in prothymocytes acts as an oncogene. Mol. Med. 3:1997;72-81
232. Ward I.M., Minn K., van Deursen J., Chen J. p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23:2003;2556-2563
233. Ward J.M., Tadesse-Heath L., Perkins S.N., Chattopadhyay S.K., Hursting S.D., Morse H.C. 3rd. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice. Lab. Invest. 79:1999;3-14
234. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., Zambetti G.P. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 14:2000;2358-2365
235. Webster G., Onions D.E., Neil J.C., Cameron E.R. Skewed T-cell receptor Vbeta8.2 expression in transgenic CD2-myc induced thymic lymphoma: A role for antigen stimulation in tumour development. Br. J. Cancer. 76:1997;739-746
236. Wehner L.E., Schroder N., Kamino K., Friedrich U., Biesinger B., Ruther U. Herpesvirus saimiri Tip gene causes T-cell lymphomas in transgenic mice. DNA Cell. Biol. 20:2001;81-88
237. Weinberg R.A. Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res. 49:1989;3713-3721
238. Wilson J.B., Bell J.L., Levine A.J. Expression of Epstein-Barr virus nuclear antigen-1 induced B-cell neoplasia in transgenic mice. EMBO J. 15:1996;3117-3126
239. Wotton S., Stewart M., Blyth K., Vaillant F., Kilbey A., Neil J.C., Cameron E.R. Proviral insertion indicates a dominant oncogenic role for Runx1AML-1 in T-cell lymphoma. Cancer Res. 62:2002;7181-7185
240. Xu X., Landesman-Bollag E., Channavajhala P.L., Seldin D.C. Murine protein kinase CK2: Gene and oncogene. Mol. Cell. Biochem. 191:1999;65-74
241. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:1996;2411-2422
242. Yan W., Young A.Z., Soares V.C., Kelley R., Benezra R., Zhuang Y. High incidence of T-cell tumors in E2A-null mice and E2AId1 double-knockout mice. Mol. Cell. Biol. 17:1997;7317-7327
243. Yang J.T., Liu C.Z., Domer P., Iannaccone P. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice. Cancer Detect. Prev. 22:1998;405-415
244. Yukawa K., Kikutani H., Inomoto T., Uehira M., Bin S.H., Akagi K., Yamamura K.-I., Kishimoto T. Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer Eμ-myc transgenic mice. J. Exp. Med. 170:1989;711-726
245. Zhang S., Lloyd R., Bowden G., Glickman B.W., de Boer J.G. Thymic lymphomas arising in msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum. Mutat. Res. 500:2002;67-74
246. Zhang Y., Finegold M.J., Porteu F., Kanteti P., Wu M.X. Development of T-cell lymphomas in Eμ-IEX-1 mice. Oncogene. 22:2003;6845-6851
247. Zhou P., Levy N.B., Xie H., Qian L., Lee C.Y., Gascoyne R.D., Craig R.W. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood. 97:2001;3902-3909
248. Zhu Y., Hollmen J., Raty R., Aalto Y., Nagy B., Elonen E., Kere J., Mannila H., Franssila K., Knuutila S. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br. J. Haematol. 119:2002;905-915
249. Zornig M., Busch G., Beneke R., Gulbins E., Lang F., Ma A., Korsmeyer S., Moroy T. Survival and death of prelymphomatous B-cells from N-mycbcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes. Oncogene. 11:1995a;2165-2174
250. Zornig M., Grzeschiczek A., Kowalski M.B., Hartmann K.U., Moroy T. Loss of FasApo-1 receptor accelerates lymphomagenesis in Eμ-L-myc transgenic mice but not in animals infected with Mo-MuLV. Oncogene. 10:1995b;2397-2401
251. Zornig M., Schmidt T., Karsunsky H., Grzeschiczek A., Moroy T. Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2. Oncogene. 12:1996;1789-1801
252. Zou X., Cong F., Coutts M., Cattoretti G., Goff S.P., Calame K. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo. Mol. Cell. Biol. 20:2000;628-633